Trung Huynh
Stock Analyst at UBS
(3.62)
# 851
Out of 4,711 analysts
30
Total ratings
60.87%
Success rate
23.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $4.00 | +225.00% | 1 | Oct 10, 2024 | |
| CABA Cabaletta Bio | Initiates: Buy | $10 | $2.38 | +320.17% | 1 | Oct 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $54 | $57.33 | -5.81% | 4 | Oct 9, 2024 | |
| INSM Insmed | Maintains: Buy | $78 → $84 | $70.44 | +19.25% | 3 | Aug 9, 2024 | |
| LLY Eli Lilly | Assumes: Buy | $612 → $710 | $767.76 | -7.52% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $144.47 | +21.13% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $263.38 | -24.06% | 3 | Jul 12, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $47 → $40 | $26.36 | +51.75% | 4 | Jun 29, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $125 → $126 | $98.05 | +28.51% | 3 | Mar 7, 2023 | |
| ABBV AbbVie | Initiates: Outperform | $170 | $175.58 | -3.18% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.51 | - | 1 | Mar 23, 2021 |
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $4.00
Upside: +225.00%
Cabaletta Bio
Oct 10, 2024
Initiates: Buy
Price Target: $10
Current: $2.38
Upside: +320.17%
Bristol-Myers Squibb Company
Oct 9, 2024
Maintains: Neutral
Price Target: $50 → $54
Current: $57.33
Upside: -5.81%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $78 → $84
Current: $70.44
Upside: +19.25%
Eli Lilly
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $767.76
Upside: -7.52%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $144.47
Upside: +21.13%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $263.38
Upside: -24.06%
Pfizer
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $26.36
Upside: +51.75%
Merck & Co.
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $98.05
Upside: +28.51%
AbbVie
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $175.58
Upside: -3.18%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.51
Upside: -